Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malato

Showing results (251-260 of 274) with videos related to

Pageof 28
Sort By:
Molecular Oncology|May 28, 2025
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumabCharles Swanton, Russell W Madison, Candice Francheska B Tambaoan, et al.
Cancer Biomarkers : Section a of Disease Markers|October 18, 2017
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatmentAlessandra Trojani, Ester Pungolino, Giuseppe Rossi, et al.
Cancers|March 28, 2025
Bone Marrow CD34+/lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy SubjectsAlessandra Trojani, Ester Pungolino, Barbara Di Camillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
High <i>BCR-ABL/GUS</i> Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose ImatinibPaolo Vigneri, Fabio Stagno, Stefania Stella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS StudyMariasanta Napolitano, Giorgia Saccullo, Alessandra Malato, et al.
International Journal of Molecular Sciences|May 9, 2019
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with ImatinibStefania Stella, Valentina Zammit, Silvia Rita Vitale, et al.
Plos One|July 19, 2019
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatmentAlessandra Trojani, Ester Pungolino, Alessandra Dal Molin, et al.
Cancer|March 3, 2018
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinibFabio Efficace, Fausto Castagnetti, Bruno Martino, et al.
Nature Communications|April 24, 2020
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myelomaHector H Huang, Ian D Ferguson, Alexis M Thornton, et al.
BMC Plant Biology|September 10, 2014
Genome-wide annotation of the soybean WRKY family and functional characterization of genes involved in response to Phakopsora pachyrhizi infectionMarta Bencke-Malato, Caroline Cabreira, Beatriz Wiebke-Strohm, et al.
Pageof 28

Showing results (251-260 of 274) with videos related to

Sort By:
Pageof 28
Molecular Oncology|May 28, 2025
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumabCharles Swanton, Russell W Madison, Candice Francheska B Tambaoan, et al.
Cancer Biomarkers : Section a of Disease Markers|October 18, 2017
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatmentAlessandra Trojani, Ester Pungolino, Giuseppe Rossi, et al.
Cancers|March 28, 2025
Bone Marrow CD34+/lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy SubjectsAlessandra Trojani, Ester Pungolino, Barbara Di Camillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
High <i>BCR-ABL/GUS</i> Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose ImatinibPaolo Vigneri, Fabio Stagno, Stefania Stella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS StudyMariasanta Napolitano, Giorgia Saccullo, Alessandra Malato, et al.
International Journal of Molecular Sciences|May 9, 2019
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with ImatinibStefania Stella, Valentina Zammit, Silvia Rita Vitale, et al.
Plos One|July 19, 2019
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatmentAlessandra Trojani, Ester Pungolino, Alessandra Dal Molin, et al.
Cancer|March 3, 2018
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinibFabio Efficace, Fausto Castagnetti, Bruno Martino, et al.
Nature Communications|April 24, 2020
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myelomaHector H Huang, Ian D Ferguson, Alexis M Thornton, et al.
BMC Plant Biology|September 10, 2014
Genome-wide annotation of the soybean WRKY family and functional characterization of genes involved in response to Phakopsora pachyrhizi infectionMarta Bencke-Malato, Caroline Cabreira, Beatriz Wiebke-Strohm, et al.
Pageof 28